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p53 Patches are Not Increased in Patients with Multiple
Nonmelanoma Skin Cancers
To the Editor:
Mutation of p53 tumor suppressor gene is considered to be a
frequent early event in nonmelanoma skin cancer (NMSC)
development. NMSC includes basal cell carcinoma (BCC) and
squamous cell carcinoma (SCC). Up to 40% of patients with
NMSC develop a second primary tumor; however, recognition of
this individual risk is currently impossible. UV irradiation is the
major carcinogen for NMSC. Chronically sun-exposed epidermis
harbors numerous mutated p53 clones that are detected as p53
patches by immunohistochemistry (Jonason et al, 1996; Ren et al,
1996). But whether they are precancerous remains open to debate.
We hypothesized that if p53 patches are precancerous lesions,
their prevalence would increase with the number of NMSC and
could serve as an individual risk marker for tumor development. In
a retrospective study of 250 cases (1996±98, Hospital St-Louis,
Paris, France) we scoped the presence or absence of p53 patches in
6±8 sections of normal peritumoral skin in patients treated for
excision of NMSC on chronically sun-exposed skin (i.e., face,
neck, and hands).
Patients were sorted into a solitary (no previous history of
NMSC) or multiple group (two or more NMSC, simultaneous or
successive). For each group the number of patients was 125 and the
median age 71. For the solitary NMSC group, ages ranged from 26
to 97, male gender was 66%, and there was BCC in 93 patients
(74%) and SCC in 32 (26%). For the multiple NMSC group, ages
ranged from 32 to 100, male gender was 72%, and there was BCC
in 106 patients (85%) and SCC in 19 (15%). Skin samples ®xed in
10% formalin were deparaf®nized and stained after antigen retrieval
in a microwave oven 15 mn, at 450 W, in tris buffer pH 7.3, using
monoclonal antibody D-O7 (Dako, code M7001, Denmark), with
the avidin-biotin-coupled immunoperoxidase staining method and
diaminobenzidine. P53 patches are de®ned as a well-demarcated
compact pattern of strong immunostaining of basal and suprabasal
keratinocytes nuclei in nondysplastic nontumoral epidermis
(Fig 1). Mayer's hematoxylin was used for counterstaining. All
slides were blind scoped for the presence of p53 patches by three
independent observers (FP, AJ, NBS). Fisher's exact test was used
to compare percentages between groups. Two sided tests were
computed, and p values of 0.05 or less were considered statistically
signi®cant (SAS software, SAS Institute, Cary, NC).
There was no signi®cant difference between the prevalence of
p53 patches of solitary versus multiple NMSC groups (66% vs 70%,
respectively, p = 0.59), neither was there a signi®cant difference
between the prevalence of p53 patches in the different age groups
(Table I).
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Figure 1. A typical p53 patch. P53 immunostaining 3 Scale bar: 40 mm.
Table I. P53 patch prevalences in normal skin around
nonmelanoma skin cancers, a series of 250 patients
Patients'
p53 patches/total
characteristics N/N %
Age (y)
Overall 169/250 68%
<50y 9/18 50%
50±59 y 24/34 71%
60±69 y 41/57 72%
70±79 y 43/63 68%
80±89 y 43/65 66%
> 90 y 9/13 69%
Tumor type
BCC 132/199 66%
SCC 37/51 73%
Multiple NMSC 87/125 70%
Solitary NMSC 82/125 66%
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The lack of signi®cant difference between the p53 patches
prevalence of solitary versus multiple NMSC suggests a lack of
association between p53 patches and the number of NMSC.
Previous studies suggested that p53 patches predispose keratinocytes
to cancer (Jonason et al, 1996). They were also observed to be more
common and larger in patients with BCC than in control subjects,
but age difference between groups in this study could account for
this difference (Tabata et al, 1999). What is more, p53 patches are
frequent and precede NMSC-formation in cancer prone animal
models (Berg et al, 1996).
P53 patches, however, are estimated to be 100.000 times as
common as dysplasia, suggesting that most of them regress or
remain stable (Ren et al, 1996, 1997). In our study we did not
consider a NMSC-free control group but it was previously shown
that p53 patches can be found in normal sun-exposed skin of
patients without any history of skin cancer (Jonason et al, 1996).
This suggests that these p53 patches could indeed be just a cognate
phenomenon of UV exposure. Evaluation of risk of additional
NMSC through p53 patches analysis would need more than just
evaluation of their presence or absence, as p53 patches could look
the same and yet have very different transformation potential.
Although there was no signi®cant difference between p53 patches
prevalence in the age groups of the patients we studied, the ®gure
observed in patients under the age of 50 was strikingly lower than
in any other age group. Lack of signi®cant increase of p53 patches
after 50 y of age suggests their appearance before the age of 50, less
sun-exposure, or a saturation phenomena for p53 mutation above
that age. Additionally differences between cell loss and cell renewal
associated with age could make the prevalence of p53 patches look
rather stable. We have shown for the ®rst time that there is no
signi®cant difference in p53 patches prevalence between BCC and
SCC. This may indicate a lack of association between p53 patches
and both types of NMSC.
Our study suggests that p53 patches cannot serve as a risk marker
for developing multiple NMSC as the p53 patches prevalence of
solitary versus multiple groups of patients are not signi®cantly
different. The commonness of p53 patches may mask important
molecular differences in their transformation capacity. Our study
underscores the importance of characterizing new markers for these
molecular differences rather than relying solely on p53 protein
stabilization.
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Underlying Disease Speci®city of Genetic Loci in Atopic
Dermatitis
To the Editor:
Atopic dermatitis is a chronic in¯ammatory skin disease. Chronic
in¯ammation is a characteristic of many disorders having an
immune or autoimmune component. Lee et al (2000) recently
mapped genetic loci for what was referred to as a major
susceptibility locus for atopic dermatitis to chromosome 3q21 (p
= 8.42 3 10±6). They also identi®ed two positive loci at 1p22 (p
= 0.0038) and 19p13 (p = 0.0035) for atopic dermatitis. Recently,
it has been noted that loci for autoimmune/in¯ammatory disorders
tend to cluster or colocalize (Vyse and Todd, 1996; Becker et al,
1998; Teuscher et al, 1998; Becker, 1999; Encinas et al, 1999;
Barnes 2000; Myerscough et al, 2000; Morel et al, 2001) suggesting,
in some cases, a common or shared locus involving underlying
immune regulatory pathways. Table I and Fig 1 show loci from
autoimmune/in¯ammatory disease studies that have been mapped
to within 10 cM of the three loci identi®ed in atopic dermatitis.
These diseases include: 1p22, coeliac disease, systemic lupus
erythematosus (SLE), Crohn's disease, multiple sclerosis; 3q21,
asthma, type 1 diabetes, rheumatoid arthritis, psoriasis, multiple
sclerosis; 19p13, Crohn's disease, and SLE. A locus at 3q21 has been
de®ned in Type 1 diabetes as IDDM 9 (Mein et al, 1998; Cornelis et
al, 1998). This colocalization of autoimmune/in¯ammatory loci at
the purported dermatitis loci suggests that these loci may not be
speci®c for atopic dermatitis per se but may de®ne loci for basic
immune regulatory mechanisms functional in these related immune
diseases. Of particular interest is the report of linkage of asthma to
3q21 (Dizier et al, 2000). Asthma and atopic dermatitis share a host
of systemic, cellular features common to the allergic diathesis, and
coexistence of the two phenotypes is high: 60%±80% of
atopic dermatitics have a history of asthma and 40% or more of
asthmatics have a history of atopic dermatitis (Bergmann et al,
1998). The high rate of coexistence of these two clinical
phenotypes complicates the search for phenotype-speci®c genes.
The authors also suggest (Lee et al, 2001) two leading candidate
genes for major atopic dermatitis in the region on 3q21; CD80
(B7.1) and CD86 (B7.2) (Fig 1A). These candidate molecules
within the atopic dermatitis locus on 3q21 interact with CD28 and
CTLA4 to provide costimulatory signals to T cells leading to
immune activation. The B7-CD28-CTLA4 pathway has been
shown to be active in all of the immune disorders described in
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